Purpose in a pandemic: Francis Van Parys, Asia-Pacific VP at Cytiva
The Covid-19 outbreak has brought challenges to the biopharma industry. Francis Van Parys, Asia-Pacific vice-president at Cytiva, is focused on ensuring that the company stays ahead of clients' quickly-evolving needs.
Add BT as a preferred source
THE biopharma supply chain is facing an unprecedented test, as countries around the world continue to battle the Covid-19 pandemic. This has stepped up the impetus for global life sciences player Cytiva, part of US-listed Danaher Corp, to invest in more infrastructure, expand its headcount and strike more partnerships, including in Asia-Pacific.
Cytiva - which has close to 8,000 employees across 40 countries - is a key provider of instruments, consumables, software and services that accelerate the development of therapeutics. Last year, it inked a deal with the US government to step up the manufacture of products to make Covid-19 vaccines.
The company was previously part of conglomerate General Electric, as GE Healthcare Life Sciences. In 2019, Danaher announced that it would acquire the business from GE for US$21.4 billion; the deal was completed in end-March 2020, with a rebranding to Cytiva.
TRENDING NOW
Trump lands in China for Xi summit with billionaire CEOs in tow
That ‘cheap’ Malaysia condo could cost Singapore buyers far more than they think
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
‘I feel so stupid’: How young Indonesians get stuck on the debt treadmill
